The São Paulo region of Brazil is the location for the latest round of filming for this year’s Global Animal Welfare Awards.

Good Call Media’s cameras have been circumnavigating the globe to interview the winners, from five different continents.

The northern São Paulo region is the location for our latest filming assignment

Fresh from filming on the east coast of Canada, we have flown to Brazil via Panama to meet the person from Latin America who has impressed the judges with their passion for animal welfare. The winner, from one of Sao Paolo’s highly resepcted universities, will travel to Barcelona, Spain to receive the award on May 4 at an event organised by the World Veterinary Association (WVA) and sponsored by global veterinary health company, Ceva Sante Animale, who also sponsored there highly successful 2017 Awards in South Korea..

Good Call Media’s Nik Wood, will host the event and will introduce a video report highlighting the work of each winner before they come up on stage to receive their award.

Our travels to illustrate the animal welfare stories, is also taking us to West Africa, Europe and China.

Watch out for the winners videos once the Awards have been handed out on May 4.

Good Call Media met a footballing legend for our latest assignment for Variety the Children’s Charity.

We can’t say too much about the reason for interviewing the former Arsenal and Scotland goalkeeper who went on to a successful TV career as a presenter and pundit but all will be revealed shortly.

Good Call Media’s Fiona Molloy interviewing soccer legend Bob Wilson

We caught up with Bob outside the famous home of Arsenal in North London and he couldn’t have been more helpful with our project.

As a player, Wilson is most noted for his 11-year playing career at Arsenal where he made over 300 appearances. Wilson as well featured as a youth and senior international for Scotland. After retiring as a player, he turned to coaching and broadcasting, presenting football programmes on television for 28 years until 2002. Wilson has also gone on to create a charity organization known as the Willow Foundation.

Our work with Variety now spans the UK. We are currently working on the Yorkshire Property Awards, a video that helps to kick off the prestigious black tie event which attracts over 1000 people from the region’s
property industry at a glittering event held in Harrogate’s Rudding Park Hotel & Spa.

Our work with Bob Wilson is connected with the London office of Variety and their own property lunch which will be held later this year.

Watch this space for further details on how Bob Wilson has helped our project.

The latest success for our client Volition, the multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers, are the interim results of a major trial – and, yet again, our cameras were there to record the event.

Click here to see the video report.

Cameron Reynolds: Volition CEO

The interim results from its first asymptomatic colorectal cancer (CRC) frontline screening study. This ongoing study is being carried out in collaboration with Hvidovre Hospital, University of Copenhagen, Denmark and involves 680 subjects from the Danish National CRC Screening Program. The interim results demonstrated that a small panel of three ELISA assays, when considered with the subjects’ ages and smoking histories, produced an area under the curve (AUC) of 83% and was able to detect 80% of Stage I CRC cases and 66% of High-Risk Adenomas (HRA) at 78% specificity, respectively.

Volition at the New York Stock Exchange

Good Call Media interviewed Cameron Reynolds, Chief Executive Officer of Volition, who commented, “After seven years of hard work, we are happy to announce these excellent early detection interim results from our ongoing front-line screening trial for colorectal cancer. Using only a small panel of three assays and considering certain limited patient variables, these data demonstrate that we can identify early stage and pre-cancerous adenomas at a high level of accuracy in an asymptomatic screening environment. Our tests use only a small amount of blood and could be added to routine blood screening regimens at a reasonable cost. We believe these are the first data to show high detection rates in a blood test, not only of early Stage I cancer, but also of the extremely important high-risk pre-cancerous adenomas. We believe that with further development, our Nu.Q^TM panel could form the basis of new CRC tests with early stage disease detection, and that our tests could become accessible to and usable by a wide section of the screening population around the world.”

Good Call Media is heading for Miami, Florida for its latest assignment.

We will be playing a key role in the New Technology Summit 2018 to be staged by our key client, Ceva Santé Animale, featuring a series of key opinion leaders, customers and Ceva personnel.

Nik Wood will host an on stage debate

Nik Wood will be hosting a major debate at the close of the event, which is being staged at the Hilton Downtown Miami between 20-22 March, 2018. We will also be filming the event and recording customer case study interviews with a series of clients and feeding regular video reports onto Ceva’s social media channels and internal news platforms. Ceva’s internal news service, Galaxy, regularly features news reports that we compile throughout the 44 different countries where the company operates.

The summit will cover latest hatchery solutions and performance challenges of tomorrow. Following on from the four previous New Technology & Vaccinology Summits, Ceva wants to give stakeholders the opportunity to exchange their views and experiences on some of the key topics, that the world’s poultry production has to face both today and tomorrow.

Ceva’s Poultry Franchise Director, Sylvain Comte said: “We would like this Summit to be a unique opportunity for you to share the latest information on the upcoming years’ antibiotic free and performance challenges in poultry production, from the perspective of primary breeders and large global production companies. A specific focus will be addressed to coccidiosis management through new vaccination solutions as part of the means to manage antibiotic free production and gut health from around the world. In addition to that, our talks will expose the most recent information and experiences on virus circulation and the added value of new technology vaccines to be launched in the North American & global markets.

Our Summit’s last day is dedicated to present recent hatchery solutions including equipment and quality recognition program that aim to ensure improved chick health. A large Experts Forum will take place at the end of the Summit in order to give you the opportunity to debate with key speakers, share experiences and enrich our common understanding on the discussed issues. Our ultimate goal is to help you to improve performance in your day-to-day activity, by providing you with the most advanced scientific and key practical information obtained in the field. We hope that you will enjoy meeting your fellow international poultry professionals and exchanging”.

Our work with Volition RX continued with a video interview to mark the company’s full 2017 fiscal year financial results and a business update.

The report included a full length interview with Volition Chief Executive Officer, Cameron Reynolds. The company has also announced the results of clinical trials and that work will be highlighted in a second video that we have shot and edited.

Click here to connect to the financial video report.

He said: “I could not be more proud of our dedicated team at Volition.  During 2017, we, together with our collaborators, have made strong progress. After seven years of hard work, earlier this week we were excited to announce excellent early detection interim results from our ongoing front-line screening trial for colorectal cancer. We believe these are the first data to show high detection rates in a simple blood test, not only of early Stage I cancer, but also of the extremely important high-risk pre-cancerous adenomas. We believe that with further development, our Nu.Q^TM panel could form the basis of new colorectal cancer tests with early stage disease detection, and that our tests could become accessible to and usable by a wide section of the screening population around the world. The whole team will be working hard towards achieving our numerous milestones in 2018.”

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics^®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.

As cancer screening programs become more widespread, Volition’s products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

Volition’s research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.